EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients

Jin Cui, Lianbang Wang, Armin Ghavamian, Xuemei Li, Gongzheng Wang, Tao Wang, Min Huang, Qi Ru, Xinya Zhao

BMC Gastroenterology · 2024

DOI: 10.1186/s12876-024-03402-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMC Gastroenterology, 2024. Verfasst von Jin Cui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Antibodies, Viral, Antibodies, Neutralizing. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China, Taishan Scholar Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) patients are at an elevated risk of developing severe coronavirus disease 2019 (COVID-19). The objective of this study was to assess antibody responses and safety profiles six months after the third dose of the inactivated acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in MASLD patients.

Methods

This study included MASLD patients and healthy volunteers without a history of SARS-CoV-2 infection. Blood samples were collected six months after receiving the third dose of the inactivated vaccine to measure the levels of neutralizing antibodies (NAbs) and anti-spike IgG antibodies against SARS-CoV-2.

Results

A total of 335 participants (214 MASLD patients and 121 healthy volunteers) were enrolled. The seroprevalence of NAb was 61.7% (132 of 214) in MASLD patients and 74.4% (90 of 121) in healthy volunteers, which was a significant difference ( p = 0.018). Statistically significant differences in IgG seroprevalence were also observed between MASLD patients and healthy volunteers ( p = 0.004). Multivariate analysis demonstrated that the severity of MASLD (OR, 2.97; 95% CI, 1.32–6.68; p = 0.009) and age (OR, 1.03; 95% CI, 1.01–1.06; p = 0.004) were independent risk factors for NAb negativity in MASLD patients. Moderate/severe MASLD patients had a lower NAb seroprevalence than mild MASLD patients (45.0% vs. 65.5%, p = 0.016).

Conclusion

Lower antibody responses were observed in MASLD patients six months after their third dose of the inactivated vaccine than in healthy volunteers, providing further assistance in monitoring patients who are more vulnerable to hypo-responsiveness to SARS-CoV-2 vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesAntibodies, ViralAntibodies, NeutralizingSARS-CoV-2Immunoglobulin GVaccines, InactivatedHumansMaleFemaleMiddle AgedAdultAgedAntibody FormationSeroepidemiologic Studies

Stichwörter der Autor:innen

Antibody responseMetabolic dysfunction-associated steatotic liver diseaseSARS-CoV-2Vaccine

Substanzen

COVID-19 VaccinesAntibodies, ViralAntibodies, NeutralizingImmunoglobulin GVaccines, InactivatedSARS-CoV-2 inactivated vaccines

Autor:innen und Institutionen

  • Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
  • Department of Radiology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China.
  • Department of Gastroenterology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.
  • Department of Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
  • Department of Ultrasound, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, 758 Hefei Road, Qingdao, Shandong, 266035, China. 543669972@qq.com.
  • Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education, Jinan, Shandong, 250021, China.

Förderung

  • Natural Science Foundation of Shandong Province
  • National Natural Science Foundation of China
  • Taishan Scholar Foundation of Shandong Province

Zitieren

APA

Cui, J., Wang, L., Ghavamian, A., Li, X., Wang, G., Wang, T., Huang, M., Ru, Q., & Zhao, X. (2024). Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients. BMC Gastroenterology. https://doi.org/10.1186/s12876-024-03402-9

Vancouver

Cui J, Wang L, Ghavamian A, Li X, Wang G, Wang T, et al. Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients. BMC Gastroenterology. 2024. doi:10.1186/s12876-024-03402-9

BibTeX
@article{Cui2024,
  author = {Cui, Jin and Wang, Lianbang and Ghavamian, Armin and Li, Xuemei and Wang, Gongzheng and Wang, Tao and Huang, Min and Ru, Qi and Zhao, Xinya},
  title = {Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients},
  journal = {BMC Gastroenterology},
  year = {2024},
  doi = {10.1186/s12876-024-03402-9}
}
Kostenlos starten →